Literature DB >> 14739633

The clinical thrombosis center and clinical thrombologist: a new US health systems paradigm for the management of venous thromboembolic disease.

Alex C Spyropoulos1, William Haire.   

Abstract

New paradigms for the diagnosis, prophylaxis, acute treatment, and ongoing management of patients with venous thromboembolic disease (VTE), a better understanding of the genotypic and phenotypic mechanisms of thrombophilic states, and the possibility of a greatly expanded armamentarium of antithrombotic therapies are necessitating a more formalized and systematic approach to VTE management. This has required many US healthcare institutions to develop piecemeal approaches in management models for VTE utilizing local champions from a variety of subspecialties. Development of a formalized Clinical Thrombosis Center from an already established Anticoagulant Management Service utilizing a clinical thrombologist, a new role for a physician who has developed expertise in anticoagulation and VTE management, presents a new paradigm in which this disease may be approached at a formalized, institutional level. Thus the clinical thrombologist working through a Clinical Thrombosis Center can develop a system-of-care approach to link the rapid advances in the field of thromboembolism to clinical applications, formulate evidence-based disease management guidelines, and conduct patient-oriented translational clinical research in VTE.

Entities:  

Mesh:

Year:  2003        PMID: 14739633     DOI: 10.1023/B:THRO.0000011378.16223.e4

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  49 in total

Review 1.  Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review.

Authors:  R D Hull; G F Pineo; P D Stein; A F Mah; S M MacIsaac; O E Dahl; M Butcher; R F Brant; W A Ghali; D Bergqvist; G E Raskob
Journal:  Ann Intern Med       Date:  2001-11-20       Impact factor: 25.391

2.  Peripheral vascular disease and the cardiovascular specialist.

Authors:  A N DeMaria
Journal:  J Am Coll Cardiol       Date:  1988-09       Impact factor: 24.094

3.  Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.

Authors:  K A Bauer; B I Eriksson; M R Lassen; A G Turpie
Journal:  N Engl J Med       Date:  2001-11-01       Impact factor: 91.245

4.  Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection.

Authors:  P S Wells; M J Kovacs; J Bormanis; M A Forgie; D Goudie; B Morrow; J Kovacs
Journal:  Arch Intern Med       Date:  1998-09-14

5.  Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison.

Authors:  M E Cromheecke; M Levi; L P Colly; B J de Mol; M H Prins; B A Hutten; R Mak; K C Keyzers; H R Büller
Journal:  Lancet       Date:  2000-07-08       Impact factor: 79.321

6.  A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.

Authors:  Bengt I Eriksson; Ann-Christin Arfwidsson; Lars Frison; Ulf G Eriksson; Anders Bylock; Peter Kälebo; Gunnar Fager; David Gustafsson
Journal:  Thromb Haemost       Date:  2002-02       Impact factor: 5.249

Review 7.  Development of oral heparin therapy for prophylaxis and treatment of deep venous thrombosis.

Authors:  S R Money; J W York
Journal:  Cardiovasc Surg       Date:  2001-06

8.  Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs.

Authors:  E Chiquette; M G Amato; H I Bussey
Journal:  Arch Intern Med       Date:  1998 Aug 10-24

9.  Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.

Authors:  M M Koopman; P Prandoni; F Piovella; P A Ockelford; D P Brandjes; J van der Meer; A S Gallus; G Simonneau; C H Chesterman; M H Prins
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 91.245

10.  Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin.

Authors:  Alex C Spyropoulos; Judith S Hurley; Gabrielle N Ciesla; Gregory de Lissovoy
Journal:  Chest       Date:  2002-07       Impact factor: 9.410

View more
  2 in total

1.  The U.S. Thrombosis and Hemostasis Centers pilot sites program.

Authors:  N F Dowling; M G Beckman; M Manco-Johnson; K Hassell; C S Philipp; L A Michaels; S Moll; J A Heit; J Penner; R Kulkarni; S Pipe; P Bockenstedt; J Andersen; S Crudder; A H James; S Zimmerman; T L Ortel
Journal:  J Thromb Thrombolysis       Date:  2007-02       Impact factor: 2.300

Review 2.  Pharmacy-managed anticoagulation: assessment of in-hospital efficacy and evaluation of financial impact and community acceptance.

Authors:  Jennifer L Donovan; Julie A Drake; Peter Whittaker; Maichi T Tran
Journal:  J Thromb Thrombolysis       Date:  2006-08       Impact factor: 2.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.